Speciality Immunoassays and Reagents
Erythropoietin (EPO) ELISA
| Erythropoietin (EPO) ELISA | Catalog # EPO.96 | |||||||
| Format | Sandwich ELISA |
|
||||||
| Size/Volume | 96 wells | |||||||
| Species | human |
|
||||||
| Sample Type | serum | |||||||
| Sample Preparation | - | |
||||||
| Sample Size | 200 uL | |||||||
| Standard Curve Range | 7.5 - 500 mU/mL | |||||||
| Sensitivity | 1.2 mU/mL | |||||||
| Assay Length | 2.5 hrs | |||||||
Intended use
The EPO ELISA is intended for the quantitative determination of Erythropoietin (EPO) in human serum. This assay is intended for research use, as an aid in the diagnosis of anemias and polycythemias. With the advent of the administration of recombinant erythropoietin as a biologic therapy to increase red blood cell mass, an erythropoietin assay may be used also to aid in the prediction and monitoring of response to recombinant erythropoietin treatment in persons with anemias.
Summary and explanation
Erythropoietin (EPO) is a heavily glycosylated protein with a molecular weight of about 30,000 - 34,000
Quantitation of serum erythropoietin concentration serves as a diagnostic adjunct in determining the cause of anemia or erythrocytosis. Aplastic anemia, hemolytic anemia and anemia due to iron deficiency all result in serum EPO elevation. Whereas, EPO levels in patients with secondary anemia due to renal failure and other disorders such as acquired immune deficiency syndrome (AIDS) are generally inappropriately low for the degree of anemia. This is mostly likely caused by an impaired ability of the diseased kidney to produce adequate quantities of EPO8. Low concentrations of EPO may give an early warning of kidney transplant rejection10. EPO also can be used to monitor AIDS patients undergoing Zidovudine (AZT) therapy. An increased concentration of EPO verifies that anemia associated with AZT therapy is due to red cell hypoplasia or apliasia10.
Polycythemia rubra vera, or primary erythrocytosis (an increase of red blood cell mass) results from unstimulated over production of erythrocytes. Hence, the increase in the hemoglobin causes decreased production of EPO, which results in subnormal levels of serum EPO9. Secondary polycythemias, which are also characterized by an increase in the total red blood cell mass, occur as a physiological response to elevated levels of circulatory EPO caused by tissue hypoxia. The hypoxia may be due to such factors as pulmonary fibrosis, cardiovascular disease, prolonged exposure to high altitude, abnormal forms of hemoglobin or drug treatment10. Some tumors produce EPO and, in these cases, EPO may be used as a tumor marker to monitor the effectiveness of treatment.
Specificity and Cross-Reactivity
Cross-reactivity in the EPO was studied by the addition of various substances to the Zero Calibrator (Calibrator A).
|
Crossreactant |
Amount of Crossreactant Added |
|
Human Transferrin |
400 g/mL |
|
Human Bilirubin (unconjugated) |
200 g/mL |
|
Human Hemoglobin |
5 mg/mL |
|
Human Alpha Globulin |
60 mg/mL |
|
Human Alpha2-Macroglobulin |
500 g/mL |
|
Human ? 1-Acid Glycoprotein, |
800 g/mL |
|
Human ? 1-Antitrypsin |
500 g/mL |
|
Triglycerides |
30 mg/mL |
|
Human Albumin |
60 mg/mL |
|
Human Gamma Globulin |
60 mg/mL |
|
ACTH (intact molecule: amino acid sequence1-39) |
5,000 pg/mL |
|
TSH |
100 IU/mL |
Product inserts are for information use only.
MDB EPO ELISA MSDS
SIGN UP and be the first to know about our new products, the next trade show,latest research... click here for more


